
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k130213
B. Purpose for Submission:
New Device
C. Measurand:
Amphetamine, Secobarbital, Oxazepam, Benzoylecgonine, Methadone, Methamphetamine,
Opiates, Phencyclidine, Cannabinoid (THC)
D. Type of Test:
Qualitative chromatographic immunoassay
E. Applicant:
LumiQuick Diagnostics Inc.
F. Proprietary and Established Names:
QuickProfile Single Drugs of Abuse Screen Device
QuickProfile Multi-Drugs of Abuse Screen Device
G. Regulatory Information:
Product Code Classification Regulation Section Panel
21 CFR part 862.3100
DKZ Class II Toxicology (91)
Amphetamine test system
21 CFR part 862.3150
DIS Class II Toxicology (91)
Barbiturate test system
21 CFR part 862.3170
JXM Class II Toxicology (91)
Benzodiazepine test system
21 CFR part 862.3250
DIO Class II Cocaine and cocaine metabolite Toxicology (91)
test system
21 CFR part 862.3620
DJR Class II Toxicology (91)
Methadone test system
1

[Table 1 on page 1]
Product Code	Classification	Regulation Section	Panel
DKZ	Class II	21 CFR part 862.3100
Amphetamine test system	Toxicology (91)
DIS	Class II	21 CFR part 862.3150
Barbiturate test system	Toxicology (91)
JXM	Class II	21 CFR part 862.3170
Benzodiazepine test system	Toxicology (91)
DIO	Class II	21 CFR part 862.3250
Cocaine and cocaine metabolite
test system	Toxicology (91)
DJR	Class II	21 CFR part 862.3620
Methadone test system	Toxicology (91)

--- Page 2 ---
21 CFR part 862.3610
DJC Class II Toxicology (91)
Methamphetamine test system
21 CFR part 862.3650
DJG Class II Toxicology (91)
Opiate test system
LCM Unclassified Phencyclidine Toxicology (91)
21 CFR part 862.3870
LDJ Class II Toxicology (91)
Cannabinoid test system.
H. Intended Use:
1. Intended use(s):
Please see indications for use below.
2. Indication(s) for use:
LumiQuick’s QuickProfile Single Drugs of Abuse and QuickProfile Multi-Drugs of
Abuse Screen Devices are rapid chromatographic immunoassays for the qualitative and
simultaneous detection of one to nine of the following drugs in a variety of
combinations in human urine. Both devices are available in test strip, dip panel, cassette
panel and cup formats. The designed cutoff concentrations and direct calibrator for
these drugs are as follows:
AMP Amphetamine 1000 ng/ml
BAR Secobarbital 300 ng/ml
BZO Oxazepam 300 ng/ml
COC Benzoylecgonine 300 ng/ml
MTD Methadone 300 ng/ml
MAMP Methamphetamine 1000 ng/ml
OPI Morphine 300 ng/ml
PCP Phencyclidine 25 ng/ml
THC THC 11-nor-Δ9-THC-9-COOH 50 ng/ml
These devices are intended for prescription use only. These assays provide only a
preliminary analytical test result. A more specific alternative chemical method must be
used in order to obtain a confirmed analytical result. Gas Chromatography / Mass
Spectrometry (GC/MS) or Liquid Chromatography / Mass Spectrometry (LC/MS) are
the preferred confirmatory method.
Clinical consideration and professional judgment should be applied to any drug of
abuse test result, particularly when preliminary positive results are indicated.
3. Special conditions for use statement(s):
For Prescription Use.
2

[Table 1 on page 2]
DJC	Class II	21 CFR part 862.3610
Methamphetamine test system	Toxicology (91)
DJG	Class II	21 CFR part 862.3650
Opiate test system	Toxicology (91)
LCM	Unclassified	Phencyclidine	Toxicology (91)
LDJ	Class II	21 CFR part 862.3870
Cannabinoid test system.	Toxicology (91)

--- Page 3 ---
4. Special instrument requirements:
Not applicable; these are visually read single use devices
I. Device Description:
The QuickProfile Single Drugs of Abuse Device and Quick Profile Multi-Drugs of Abuse
Screen Device are one-step, colloidal gold based chromatographic immunoassays for the
rapid, qualitative detection of Amphetamine, Barbiturates, Benzodiazepines, Cocaine,
Methadone, Methamphetamine, Opiates, Phencyclidine, and Marijuana in human urine.
The single and multi-test devices contain one or more than one test strip. Both devices are
available in test strip, dip panel, cassette panel and cup formats.
J. Substantial Equivalence Information:
1. Predicate device name(s):
Innovacon Spectrum II Test Card
2. Predicate 510(k) number(s):
k061718
3. Comparison with predicate:
Innovacon
QuickProfile Single Drugs of Abuse and
Spectrum II
QuickProfile Multi-Drugs of Abuse
Item Test Card
Screen Devices
(Predicate-
(Candidate Device)
k061718)
Rapid chromatographic immunoassays for the
qualitative and simultaneous detection of one
or more drugs of abuse in a variety of
Intended Use Same
combinations in human urine.
The devices are intended for prescription use
only.
Method of Test card;
Test strip, Dip panel, Cassette panel, and Cup
Measurement Cup
Test Principle Enzyme Immunoassay (EIA) Same
Sample Matrix Urine Same
Time 5 Minutes Same
Cutoff Levels Amphetamine 1000 ng/ml Same
3

[Table 1 on page 3]
Item	QuickProfile Single Drugs of Abuse and
QuickProfile Multi-Drugs of Abuse
Screen Devices
(Candidate Device)	Innovacon
Spectrum II
Test Card
(Predicate-
k061718)
Intended Use	Rapid chromatographic immunoassays for the
qualitative and simultaneous detection of one
or more drugs of abuse in a variety of
combinations in human urine.
The devices are intended for prescription use
only.	Same
Method of
Measurement	Test strip, Dip panel, Cassette panel, and Cup	Test card;
Cup
Test Principle	Enzyme Immunoassay (EIA)	Same
Sample Matrix	Urine	Same
Time	5 Minutes	Same
Cutoff Levels	Amphetamine 1000 ng/ml	Same

--- Page 4 ---
Secobarbital 300 ng/ml
Oxazepam 300 ng/ml
Benzoylecgonine 300 ng/ml
Methadone 300 ng/ml
Methamphetamine 1000 ng/ml
Opiates 300 ng/ml
Phencyclidine 25 ng/ml
THC 50 ng/ml
K. Standard/Guidance Document Referenced (if applicable):
None were referenced.
L. Test Principle:
The QuickProfile Single Drugs of Abuse and QuickProfile Multi-Drugs of Abuse Screen
Device are one-step immunoassays in which chemically labeled drugs (drug-protein
conjugates) compete for limited antibody binding sites with drugs that may be present in
urine. The single and multi-test devices contain one or more than one test strips (single
drug or 2 drugs per test strip) in the dip panel, cassette panel and cup formats. The drug-
protein conjugates are pre-coated on the test band of the membrane and the drug mouse
antibody-colloidal gold conjugate pads are placed at one end of the membrane. In the
absence of drugs in the urine, the solution of the colored antibody-colloidal gold conjugates
move along with the sample solution by capillary action to the immobilized drug-protein
conjugate zones on the test band region. The colored antibody-gold conjugates then attach
to the drug-protein conjugates to form visible lines as the antibodies complex with the drug
conjugates. Therefore, the formation of the visible precipitant in the test band occurs when
the test urine is negative for the drug. When drug is present in the urine, the
drug/metabolite antigen competes with drug-protein conjugates on the test band region for
the limited antibody on the colored drug antibody-colloidal gold conjugate pad. When a
sufficient concentration of the drug is present, it will fill the limited antibody binding sites.
This will prevent attachment of the colored antibody (drug-protein conjugate)-colloidal
gold conjugate to the drug-protein conjugate zone on the test band region. Therefore,
absence of the color band on the test region indicates a positive result.
A control band is added to the immunochromatographic membrane strip at the control
region (C) to indicate that the test has performed properly. This control line should always
appear regardless of the presence of drug or metabolite.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
1. Intra-assay precision around the cutoff
4

[Table 1 on page 4]
	Secobarbital 300 ng/ml	
	Oxazepam 300 ng/ml	
	Benzoylecgonine 300 ng/ml	
	Methadone 300 ng/ml	
	Methamphetamine 1000 ng/ml	
	Opiates 300 ng/ml	
	Phencyclidine 25 ng/ml	
	THC 50 ng/ml	

--- Page 5 ---
A commercially available panel (blinded) of GC/MS confirmed urine-based
control samples containing multiple drugs were used for the study. These
samples contained the following concentrations: Negative, 50%, 75%, 100%,
125%, 150%, and 200% of the cutoff level of drug analytes. Two additional
concentrations were prepared using these controls to generate samples at 25%
and 175% of the cut off level. Test Strip, Dip Panel, Cassette Panel and Cup
formats, for 9 target drugs were tested. Each control level was tested in
duplicates for ten consecutive days, 3 lots per format, one device lot per
professional (3 professionals). Results were consistent between lots.
Representative lot results are presented in the tables below:
Amphetamine (AMP):
Test Strip
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
250 25% 20 20 100
500 50% 20 20 100
750 75% 20 20 100
1000 100% 20 20 100
1250 125% 20 20 100
1500 150% 20 20 100
1750 175% 20 20 100
2000 200% 20 20 100
Dip Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
250 25% 20 20 100
500 50% 20 20 100
750 75% 20 20 100
1000 100% 20 20 100
1250 125% 20 20 100
1500 150% 20 20 100
1750 175% 20 20 100
2000 200% 20 20 100
Cassette Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
250 25% 20 20 100
500 50% 20 20 100
750 75% 20 20 100
5

[Table 1 on page 5]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
250	25%	20	20		100
500	50%	20	20		100
750	75%	20	20		100
1000	100%	20		20	100
1250	125%	20		20	100
1500	150%	20		20	100
1750	175%	20		20	100
2000	200%	20		20	100

[Table 2 on page 5]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
250	25%	20	20		100
500	50%	20	20		100
750	75%	20	20		100
1000	100%	20		20	100
1250	125%	20		20	100
1500	150%	20		20	100
1750	175%	20		20	100
2000	200%	20		20	100

[Table 3 on page 5]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
250	25%	20	20		100
500	50%	20	20		100
750	75%	20	20		100

--- Page 6 ---
1000 100% 20 20 100
1250 125% 20 20 100
1500 150% 20 20 100
1750 175% 20 20 100
2000 200% 20 20 100
Cup
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
250 25% 20 20 100
500 50% 20 20 100
750 75% 20 20 100
1000 100% 20 20 100
1250 125% 20 20 100
1500 150% 20 20 100
1750 175% 20 20 100
2000 200% 20 20 100
Opiates 300 (OPI):
Test Strip
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Dip Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
6

[Table 1 on page 6]
1000	100%	20		20	100
1250	125%	20		20	100
1500	150%	20		20	100
1750	175%	20		20	100
2000	200%	20		20	100

[Table 2 on page 6]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
250	25%	20	20		100
500	50%	20	20		100
750	75%	20	20		100
1000	100%	20		20	100
1250	125%	20		20	100
1500	150%	20		20	100
1750	175%	20		20	100
2000	200%	20		20	100

[Table 3 on page 6]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 4 on page 6]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

--- Page 7 ---
Cassette Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Cup
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Benzodiazepines (BZO):
Test Strip
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Dip Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
7

[Table 1 on page 7]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 2 on page 7]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 3 on page 7]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 4 on page 7]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100

--- Page 8 ---
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Cassette Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Cup
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Cocaine (COC):
Test Strip
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
8

[Table 1 on page 8]
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 2 on page 8]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 3 on page 8]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 4 on page 8]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100

--- Page 9 ---
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Dip Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Cassette Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Cup
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
9

[Table 1 on page 9]
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 2 on page 9]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 3 on page 9]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 4 on page 9]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

--- Page 10 ---
Methamphetamine (MAMP):
Test Strip
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
250 25% 20 20 100
500 50% 20 20 100
750 75% 20 20 100
1000 100% 20 20 100
1250 125% 20 20 100
1500 150% 20 20 100
1750 175% 20 20 100
2000 200% 20 20 100
Dip Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
250 25% 20 20 100
500 50% 20 20 100
750 75% 20 20 100
1000 100% 20 20 100
1250 125% 20 20 100
1500 150% 20 20 100
1750 175% 20 20 100
2000 200% 20 20 100
Cassette Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
250 25% 20 20 100
500 50% 20 20 100
750 75% 20 20 100
1000 100% 20 20 100
1250 125% 20 20 100
1500 150% 20 20 100
1750 175% 20 20 100
2000 200% 20 20 100
Cup
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
250 25% 20 20 100
10

[Table 1 on page 10]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
250	25%	20	20		100
500	50%	20	20		100
750	75%	20	20		100
1000	100%	20		20	100
1250	125%	20		20	100
1500	150%	20		20	100
1750	175%	20		20	100
2000	200%	20		20	100

[Table 2 on page 10]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
250	25%	20	20		100
500	50%	20	20		100
750	75%	20	20		100
1000	100%	20		20	100
1250	125%	20		20	100
1500	150%	20		20	100
1750	175%	20		20	100
2000	200%	20		20	100

[Table 3 on page 10]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
250	25%	20	20		100
500	50%	20	20		100
750	75%	20	20		100
1000	100%	20		20	100
1250	125%	20		20	100
1500	150%	20		20	100
1750	175%	20		20	100
2000	200%	20		20	100

[Table 4 on page 10]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
250	25%	20	20		100

--- Page 11 ---
500 50% 20 20 100
750 75% 20 20 100
1000 100% 20 20 100
1250 125% 20 20 100
1500 150% 20 20 100
1750 175% 20 20 100
2000 200% 20 20 100
Marijuana (THC):
Test Strip
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
12.5 25% 20 20 100
25 50% 20 20 100
37.5 75% 20 20 100
50 100% 20 20 100
62.5 125% 20 20 100
75 150% 20 20 100
87.5 175% 20 20 100
100 200% 20 20 100
Dip Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
12.5 25% 20 20 100
25 50% 20 20 100
37.5 75% 20 20 100
50 100% 20 20 100
62.5 125% 20 20 100
75 150% 20 20 100
87.5 175% 20 20 100
100 200% 20 20 100
Cassette Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
12.5 25% 20 20 100
25 50% 20 20 100
37.5 75% 20 20 100
50 100% 20 20 100
62.5 125% 20 20 100
75 150% 20 20 100
11

[Table 1 on page 11]
500	50%	20	20		100
750	75%	20	20		100
1000	100%	20		20	100
1250	125%	20		20	100
1500	150%	20		20	100
1750	175%	20		20	100
2000	200%	20		20	100

[Table 2 on page 11]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
12.5	25%	20	20		100
25	50%	20	20		100
37.5	75%	20	20		100
50	100%	20		20	100
62.5	125%	20		20	100
75	150%	20		20	100
87.5	175%	20		20	100
100	200%	20		20	100

[Table 3 on page 11]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
12.5	25%	20	20		100
25	50%	20	20		100
37.5	75%	20	20		100
50	100%	20		20	100
62.5	125%	20		20	100
75	150%	20		20	100
87.5	175%	20		20	100
100	200%	20		20	100

[Table 4 on page 11]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
12.5	25%	20	20		100
25	50%	20	20		100
37.5	75%	20	20		100
50	100%	20		20	100
62.5	125%	20		20	100
75	150%	20		20	100

--- Page 12 ---
87.5 175% 20 20 100
100 200% 20 20 100
Cup
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
12.5 25% 20 20 100
25 50% 20 20 100
37.5 75% 20 20 100
50 100% 20 20 100
62.5 125% 20 20 100
75 150% 20 20 100
87.5 175% 20 20 100
100 200% 20 20 100
Barbiturate (BAR):
Test Strip
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Dip Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
12

[Table 1 on page 12]
87.5	175%	20		20	100
100	200%	20		20	100

[Table 2 on page 12]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
12.5	25%	20	20		100
25	50%	20	20		100
37.5	75%	20	20		100
50	100%	20		20	100
62.5	125%	20		20	100
75	150%	20		20	100
87.5	175%	20		20	100
100	200%	20		20	100

[Table 3 on page 12]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 4 on page 12]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

--- Page 13 ---
Cassette Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Cup
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Phencyclidine (PCP):
Test Strip
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
6.25 25% 20 20 100
12.5 50% 20 20 100
18.75 75% 20 20 100
25 100% 20 20 100
31.25 125% 20 20 100
37.5 150% 20 20 100
43.75 175% 20 20 100
50 200% 20 20 100
Dip Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
6.25 25% 20 20 100
13

[Table 1 on page 13]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 2 on page 13]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 3 on page 13]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
6.25	25%	20	20		100
12.5	50%	20	20		100
18.75	75%	20	20		100
25	100%	20		20	100
31.25	125%	20		20	100
37.5	150%	20		20	100
43.75	175%	20		20	100
50	200%	20		20	100

[Table 4 on page 13]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
6.25	25%	20	20		100

--- Page 14 ---
12.5 50% 20 20 100
18.75 75% 20 20 100
25 100% 20 20 100
31.25 125% 20 20 100
37.5 150% 20 20 100
43.75 175% 20 20 100
50 200% 20 20 100
Cassette Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
6.25 25% 20 20 100
12.5 50% 20 20 100
18.75 75% 20 20 100
25 100% 20 20 100
31.25 125% 20 20 100
37.5 150% 20 20 100
43.75 175% 20 20 100
50 200% 20 20 100
Cup
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
6.25 25% 20 20 100
12.5 50% 20 20 100
18.75 75% 20 20 100
25 100% 20 20 100
31.25 125% 20 20 100
37.5 150% 20 20 100
43.75 175% 20 20 100
50 200% 20 20 100
Methadone (MTD):
Test Strip
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
14

[Table 1 on page 14]
12.5	50%	20	20		100
18.75	75%	20	20		100
25	100%	20		20	100
31.25	125%	20		20	100
37.5	150%	20		20	100
43.75	175%	20		20	100
50	200%	20		20	100

[Table 2 on page 14]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
6.25	25%	20	20		100
12.5	50%	20	20		100
18.75	75%	20	20		100
25	100%	20		20	100
31.25	125%	20		20	100
37.5	150%	20		20	100
43.75	175%	20		20	100
50	200%	20		20	100

[Table 3 on page 14]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
6.25	25%	20	20		100
12.5	50%	20	20		100
18.75	75%	20	20		100
25	100%	20		20	100
31.25	125%	20		20	100
37.5	150%	20		20	100
43.75	175%	20		20	100
50	200%	20		20	100

[Table 4 on page 14]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100

--- Page 15 ---
525 175% 20 20 100
600 200% 20 20 100
Dip Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Cassette Panel
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
Cup
Conc Cut-off % No. of No. of No. of
% Agreement
(ng/ml) Tested Negative Preliminary
0 Negative 20 20 100
75 25% 20 20 100
150 50% 20 20 100
225 75% 20 20 100
300 100% 20 20 100
375 125% 20 20 100
450 150% 20 20 100
525 175% 20 20 100
600 200% 20 20 100
b. Linearity/assay reportable range:
Not Applicable.
15

[Table 1 on page 15]
525	175%	20		20	100
600	200%	20		20	100

[Table 2 on page 15]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 3 on page 15]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

[Table 4 on page 15]
Conc
(ng/ml)	Cut-off %	No. of
Tested	No. of
Negative	No. of
Preliminary	% Agreement
0	Negative	20	20		100
75	25%	20	20		100
150	50%	20	20		100
225	75%	20	20		100
300	100%	20		20	100
375	125%	20		20	100
450	150%	20		20	100
525	175%	20		20	100
600	200%	20		20	100

--- Page 16 ---
c. Traceability, Stability, Expected values (controls, , calibrators, or methods):
External controls are not supplied with this device. The labeling states that users
should follow the appropriate federal, state, and local guidelines concerning the
running of external quality controls.
Stability
Accelerated and real time studies have been conducted for the QuickProfile Single
Drug of Abuse and QuickProfile Multi-Drugs of Abuse Screen Devices. Protocols
and acceptance criteria were reviewed and found to be acceptable. The
manufacturer claims the following expiration date for the unopened (shelf-life)
stability: 18 months for all formats (test strip, cassette panel, cup and dip panel).
For open pouch stability the user is instructed in the labeling as follows: “Do not
open pouches until ready to perform the assay.”
d. Detection limit:
Not applicable.
e. Analytical specificity:
Interference was evaluated by spiking various concentrations of each substance into
GC/MS confirmed urine-based control material at the following levels: Negative,
50% and 150% of cutoff. Compounds chemically related to each drug were tested
to determine possible interference. Each compound was tested in three replicates.
The highest concentration at which each substance does not interfere is presented
below for each substance:
Concentration
Compound
(µg/mL)
Acetaminophen 100
Acetone 200
Albumin 50,000
Amitriptyline 100
Ampicillin 100
Aspartame 100
Aspirin 100
Atropine 100
Benzocaine 100
Bilirubin 150
Caffeine 100
Chloroquine 100
Chlorpheniramine 100
Creatinine 100
Dextromethorphan 100
Dextrorphan tartrate 100
4-Dimethyllaminoantiyrine 100
16

[Table 1 on page 16]
Compound	Concentration
(µg/mL)
Acetaminophen	100
Acetone	200
Albumin	50,000
Amitriptyline	100
Ampicillin	100
Aspartame	100
Aspirin	100
Atropine	100
Benzocaine	100
Bilirubin	150
Caffeine	100
Chloroquine	100
Chlorpheniramine	100
Creatinine	100
Dextromethorphan	100
Dextrorphan tartrate	100
4-Dimethyllaminoantiyrine	100

--- Page 17 ---
Dopamine 100
(+/-)-Ephedrine 100
(-)-Ephedrine 100
Erythromycin 100
Ethanol 1000
Furosemide 100
Glucose 1,200
Guaiacol Glyceryl Ether 100
Hemoglobin 200,000
Ibuprofen 100
Imipramine 100
Isoproterenol 100
Lidocaine 100
Methadone 100
N-Methyl-Ephedrine 100
(+)-Naproxen 100
Oxalic Acid 100
Penicillin-G 100
Pheniramine 100
Phenothiazine 100
L-Phenylephrine 100
b-Phenylethyl-amine 100
Procaine 100
Protonix 100
Pseudoephedrine 100
Ranitidine 100
Quinidine 100
Sulindac 100
Tyramine 100
Vitamin C (Ascorbic Acid) 100
Cross-reactivity was tested by adding various drugs, drug metabolites, and other
structure-similar compounds that are likely to be present in the urine. All
compounds were prepared in a drug-free pool of human urine. Each compound that
indicated positive results was diluted until negative results were observed and the
minimum level of cross reactivity was identified. Each compound was tested in
replicates of three. Results are provided below:
Concentration % Cross
Amphetamine related compounds
(ng/ml) Reactivity
d-Amphetamine 1000 100
l-Amphetamine 30,000 3.33
d-Methamphetamine >100,000 < 1
l-Methamphetamine >100,000 < 1
3,4-Methylenediioxyamphetamine 2,500
40
(MDA)
3,4-Methylenediioxy-methamphetamine >100,000
< 1
(MDMA)
17

[Table 1 on page 17]
Dopamine	100
(+/-)-Ephedrine	100
(-)-Ephedrine	100
Erythromycin	100
Ethanol	1000
Furosemide	100
Glucose	1,200
Guaiacol Glyceryl Ether	100
Hemoglobin	200,000
Ibuprofen	100
Imipramine	100
Isoproterenol	100
Lidocaine	100
Methadone	100
N-Methyl-Ephedrine	100
(+)-Naproxen	100
Oxalic Acid	100
Penicillin-G	100
Pheniramine	100
Phenothiazine	100
L-Phenylephrine	100
b-Phenylethyl-amine	100
Procaine	100
Protonix	100
Pseudoephedrine	100
Ranitidine	100
Quinidine	100
Sulindac	100
Tyramine	100
Vitamin C (Ascorbic Acid)	100

--- Page 18 ---
3,4-Methylenediioxyethylamphetamine >100,000
< 1
(MDEA)
Concentration % Cross
Opiates 300 related compounds
(ng/ml) Reactivity
Morphine 300 100
Codeine 300 100
Diacetyl Morphin (Heroin) 1,250 24
Ethylmorphine 300 100
Hydromorphone 1,000 30
Hydrocodone 1,250 24
Oxymorphon 10,000 3
Oxycodone >100,000 < 0.3
Merperidine >100,000 <0.3
6-Acetylmorphine 100 300
Morphine-3-glucuronid 300 100
Nalbupine >100,000 < 0.3
Nalorphine 750 40
Naloxone 25,000 1.2
Natrexone 100,000 0.3
Normorphone 2,000 15
Procaine >100,000 < 0.3
Concentration % Cross
Benzodiazepines related compounds
(ng/ml) Reactivity
Oxazepam 300 100
Alprazolam 300 100
Bromazepam 1,000 30
Chlordiazepoxide 300 100
Clobazam 300 100
Clonazepam 2,000 15
Diazepam 300 100
Estazolam 500 60
Fentanyl >100,000 < 0.3
Flunitrazepam 300 100
Flurazepam >100,000 < 0.3
Lorazepam 1,000 30
Lormetazepam 1,000 30
Midazolam >100,000 < 0.3
Nitrazepam 100 300
Nordiazepam 500 60
Prazepam >100,000 < 0.3
Temazepam 300 100
Triazolam 1,000 30
18

--- Page 19 ---
Concentration % Cross
Cocaine related compounds
(ng/ml) Reactivity
Benzoylecgonine 300 100
Cocaine 300 100
Ecgonine >100,000 < 0.3
Ecgonine Methyl Ester >100,000 < 0.3
Concentration % Cross
Methamphetamine related compounds
(ng/ml) Reactivity
(+)-Methamphetamine 1,000 100
d-Amphetamine 100,000 1.00
Chloroquine >100,000 < 1
(+/-) Ephedrine >100,000 < 1
(-)-Methamphetamine 10,000 10
3,4-Methylenediioxy-methamphetamine < 1
1,000
(MDMA)
3,4-Methylenediioxyamphetamine 100
>100,000
(MDA)
3,4-Methylenediioxyethylamphetamine 10
10,000
(MDEA)
(+/-) N-Methyl-1-(3,4- 2
methylenedioxyphenyl)-2-butanamine 50,000
(MBDB)
Concentration % Cross
THC related compounds
(ng/ml) Reactivity
11-nor-Δ9-THC-9-COOH 50 100
Δ8-tetrahydrocannabinol 50,000 0.10
Δ9-tetrahydrocannabinol 500 10
11-hydroxy-Δ9-THC 50,000 0.10
Cannabinol >100,000 < 0.05
Cannabidiol >100,000 < 0.05
Concentration % Cross
Barbiturates related compounds
(ng/ml) Reactivity
Secobarbital 300 100
Amobarbital 150 200
Butalbital 2,000 15
Pentobarbital 300 100
Phenobarbital 300 100
Concentration % Cross
PCP related compounds
(ng/ml) Reactivity
Phencyclidine 25 100
Cis-Tramadol 10,000 0.25
19

--- Page 20 ---
Dextromethorphan 50,000 0.05
N-Desmethyl-cis-tramadol 10,000 0.25
Concentration % Cross
Methadone related compounds
(ng/ml) Reactivity
Methadone 300 100
Doxylamine >100,000 < 0.3
EDDP >100,000 < 0.3
pH and Specific Gravity
To test for possible positive and/or negative interference from pH, urine samples
containing drug concentrations of 0%, 75%, 125% and 150% of cutoff and with a
pH of 3.0, 5.0, 6.5, 7.5 and 8.5 were used. Three replicates per sample were tested.
No positive or negative interference due to pH was observed.
To test for possible positive and/or negative interference from specific gravity,
urine samples having specific gravity of 1.000-1.009, 1.010-1.020, 1.021-1.029 and
≥1.030 were used. The samples were spiked to negative, 75%, 125%, and 150% of
cutoff of all drug analytes. No positive or negative interference due to specific
gravity was observed.
f. Assay cut-off:
A separate cut-off study was conducted similarly to the precision study above, with
similar results obtained. See precision studies above in section M.1.a.
2. Comparison studies:
a. Method comparison with predicate device:
The study was performed using commercially available blinded-level and unaltered
clinical urine specimens confirmed by GC/MS or LC/MS methodology. Tests were
performed by 3 lab technicians. A minimum of 41 negative urine and 43 positive
urine samples for each analyte (drug) were tested in duplicate in the following
formats: Cup, Dip Panel, Test Strip and Cassette Panel. The results are presented
below:
Amphetamine comparison with GC/MS value:
Drug- -50% of the Cut-off to
< -50% of > +50% of %
AMP Free cut-off to the +50% of
the cut-off the cut-off Agreement
Urine cut-off the cutoff
+ 0 0 0 10 40 100.0
Cup
-
34 5 10 0 0 100.0
Dip + 0 0 0 10 40 100.0
Panel - 34 5 10 0 0 100.0
20

[Table 1 on page 20]
AMP		Drug-
Free
Urine	< -50% of
the cut-off	-50% of the
cut-off to the
cut-off	Cut-off to
+50% of
the cutoff	> +50% of
the cut-off	%
Agreement
Cup	+	0	0	0	10	40	100.0
	-	34	5	10	0	0	100.0
Dip
Panel	+	0	0	0	10	40	100.0
	-	34	5	10	0	0	100.0

--- Page 21 ---
Test + 0 0 0 10 40 100.0
Strip - 34 5 10 0 0 100.0
Cas sette + 0 0 0 10 40 100.0
Pa nel - 34 5 10 0 0 100.0
Barbiturates (BAR) comparison with GC/MS value:
Drug- -50% of the Cut-off to
< -50% of > +50% of %
BAR Free cut-off to the +50% of
(-) the cut-off the cut-off Agreement
Urine cut-off the cutoff
+ 0 0 0 5 41 100.0
Cup
- 34 16 6 0 0 100.0
+ 0 0 0 5 41 100.0
Dip Panel
- 34 16 6 0 0 100.0
+ 0 0 0 5 41 100.0
Test Strip
- 34 16 6 0 0 100.0
Cassette + 0 0 0 5 41 100.0
Panel - 34 16 6 0 0 100.0
Benzodiazepines (BZO) comparison with GC/MS value:
Drug- -50% of the Cut-off to
< -50% of > +50% of %
BZO Free cut-off to the +50% of
the cut-off the cut-off Agreement
Urine cut-off the cutoff
+ 0 0 0 10 59 100.0
Cup
- 34 8 12 0 0 100.0
+ 0 0 0 10 59 100.0
Dip Panel
- 34 8 12 0 0 100.0
+ 0 0 0 10 59 100.0
Test Strip
- 34 8 12 0 0 100.0
Cassette + 0 0 0 10 59 100.0
Panel - 34 8 12 0 0 100.0
Cocaine (COC) comparison with GC/MS value:
Drug- -50% of the Cut-off to
< -50% of > +50% of %
COC Free cut-off to the +50% of
the cut-off the cut-off Agreement
Urine cut-off the cutoff
+ 0 0 0 9 39 100.0
Cup
- 34 5 10 0 0 100.0
+ 0 0 0 9 39 100.0
Dip Panel
- 34 5 10 0 0 100.0
+ 0 0 0 9 39 100.0
Test Strip
- 34 5 10 0 0 100.0
Cassette + 0 0 0 9 39 100.0
Panel - 34 5 10 0 0 100.0
21

[Table 1 on page 21]
Test
Strip	+	0	0	0	10	40	100.0
	-	34	5	10	0	0	100.0
Cas sette
Pa nel	+	0	0	0	10	40	100.0
	-	34	5	10	0	0	100.0

[Table 2 on page 21]
BAR
(-)		Drug-
Free
Urine	< -50% of
the cut-off	-50% of the
cut-off to the
cut-off	Cut-off to
+50% of
the cutoff	> +50% of
the cut-off	%
Agreement
Cup	+	0	0	0	5	41	100.0
	-	34	16	6	0	0	100.0
Dip Panel	+	0	0	0	5	41	100.0
	-	34	16	6	0	0	100.0
Test Strip	+	0	0	0	5	41	100.0
	-	34	16	6	0	0	100.0
Cassette
Panel	+	0	0	0	5	41	100.0
	-	34	16	6	0	0	100.0

[Table 3 on page 21]
BZO		Drug-
Free
Urine	< -50% of
the cut-off	-50% of the
cut-off to the
cut-off	Cut-off to
+50% of
the cutoff	> +50% of
the cut-off	%
Agreement
Cup	+	0	0	0	10	59	100.0
	-	34	8	12	0	0	100.0
Dip Panel	+	0	0	0	10	59	100.0
	-	34	8	12	0	0	100.0
Test Strip	+	0	0	0	10	59	100.0
	-	34	8	12	0	0	100.0
Cassette
Panel	+	0	0	0	10	59	100.0
	-	34	8	12	0	0	100.0

[Table 4 on page 21]
COC		Drug-
Free
Urine	< -50% of
the cut-off	-50% of the
cut-off to the
cut-off	Cut-off to
+50% of
the cutoff	> +50% of
the cut-off	%
Agreement
Cup	+	0	0	0	9	39	100.0
	-	34	5	10	0	0	100.0
Dip Panel	+	0	0	0	9	39	100.0
	-	34	5	10	0	0	100.0
Test Strip	+	0	0	0	9	39	100.0
	-	34	5	10	0	0	100.0
Cassette
Panel	+	0	0	0	9	39	100.0
	-	34	5	10	0	0	100.0

--- Page 22 ---
Methadone (MTD) comparison with GC/MS value:
Drug- -50% of the Cut-off to
< -50% of > +50% of %
MTD Free cut-off to the +50% of
the cut-off the cut-off Agreement
Urine cut-off the cutoff
+ 0 0 0 8 35 100.0
Cup
- 34 5 10 0 0 100.0
+ 0 0 0 8 35 100.0
Dip Panel
- 34 5 10 0 0 100.0
+ 0 0 0 8 35 100.0
Test Strip
- 34 5 10 0 0 100.0
Cassette + 0 0 0 8 35 100.0
Panel - 34 5 10 0 0 100.0
Methamphetamine (MAMP) comparison with GC/MS value:
Drug- -50% of the Cut-off to
< -50% of > +50% of %
MAMP Free cut-off to the +50% of
the cut-off the cut-off Agreement
Urine cut-off the cutoff
+ 0 0 0 10 40 100.0
Cup
- 34 5 10 0 0 100.0
+ 0 0 0 10 40 100.0
Dip Panel
- 34 5 10 0 0 100.0
+ 0 0 0 10 40 100.0
Test Strip
- 34 5 10 0 0 100.0
Cassette + 0 0 0 10 40 100.0
Panel - 34 5 10 0 0 100.0
Opiates 300 (OPI) comparison with GC/MS value:
Drug- -50% of the Cut-off to
< -50% of > +50% of %
OPI 300 Free cut-off to the +50% of
the cut-off the cut-off Agreement
Urine cut-off the cutoff
+ 0 0 0 10 39 100.0
Cup
- 34 5 10 0 0 100.0
+ 0 0 0 10 39 100.0
Dip Panel
- 34 5 10 0 0 100.0
+ 0 0 0 10 39 100.0
Test Strip
- 34 5 10 0 0 100.0
Cassette + 0 0 0 10 39 100.0
Panel - 34 5 10 0 0 100.0
Phencyclidine (PCP) comparison with GC/MS value:
Drug- -50% of the Cut-off to
< -50% of > +50% of %
PCP Free cut-off to the +50% of
the cut-off the cut-off Agreement
Urine cut-off the cutoff
+ 0 0 0 4 42 100.0
Cup
- 34 2 5 0 0 100.0
Dip Panel + 0 0 0 4 42 100.0
22

[Table 1 on page 22]
MTD		Drug-
Free
Urine	< -50% of
the cut-off	-50% of the
cut-off to the
cut-off	Cut-off to
+50% of
the cutoff	> +50% of
the cut-off	%
Agreement
Cup	+	0	0	0	8	35	100.0
	-	34	5	10	0	0	100.0
Dip Panel	+	0	0	0	8	35	100.0
	-	34	5	10	0	0	100.0
Test Strip	+	0	0	0	8	35	100.0
	-	34	5	10	0	0	100.0
Cassette
Panel	+	0	0	0	8	35	100.0
	-	34	5	10	0	0	100.0

[Table 2 on page 22]
MAMP		Drug-
Free
Urine	< -50% of
the cut-off	-50% of the
cut-off to the
cut-off	Cut-off to
+50% of
the cutoff	> +50% of
the cut-off	%
Agreement
Cup	+	0	0	0	10	40	100.0
	-	34	5	10	0	0	100.0
Dip Panel	+	0	0	0	10	40	100.0
	-	34	5	10	0	0	100.0
Test Strip	+	0	0	0	10	40	100.0
	-	34	5	10	0	0	100.0
Cassette
Panel	+	0	0	0	10	40	100.0
	-	34	5	10	0	0	100.0

[Table 3 on page 22]
OPI 300		Drug-
Free
Urine	< -50% of
the cut-off	-50% of the
cut-off to the
cut-off	Cut-off to
+50% of
the cutoff	> +50% of
the cut-off	%
Agreement
Cup	+	0	0	0	10	39	100.0
	-	34	5	10	0	0	100.0
Dip Panel	+	0	0	0	10	39	100.0
	-	34	5	10	0	0	100.0
Test Strip	+	0	0	0	10	39	100.0
	-	34	5	10	0	0	100.0
Cassette
Panel	+	0	0	0	10	39	100.0
	-	34	5	10	0	0	100.0

[Table 4 on page 22]
PCP		Drug-
Free
Urine	< -50% of
the cut-off	-50% of the
cut-off to the
cut-off	Cut-off to
+50% of
the cutoff	> +50% of
the cut-off	%
Agreement
Cup	+	0	0	0	4	42	100.0
	-	34	2	5	0	0	100.0
Dip Panel	+	0	0	0	4	42	100.0

--- Page 23 ---
- 34 2 5 0 0 100.0
+ 0 0 0 4 42 100.0
Test Strip
- 34 2 5 0 0 100.0
Cassette + 0 0 0 4 42 100.0
Panel - 34 2 5 0 0 100.0
Marijuana (THC) comparison with GC/MS value:
Drug- -50% of the Cut-off to
< -50% of > +50% of %
THC Free cut-off to the +50% of
the cut-off the cut-off Agreement
Urine cut-off the cutoff
+ 0 0 0 10 37 100.0
Cup
- 34 5 10 0 0 100.0
+ 0 0 0 10 37 100.0
Dip Panel
- 34 5 10 0 0 100.0
+ 0 0 0 10 37 100.0
Test Strip
- 34 5 10 0 0 100.0
Cassette + 0 0 0 10 37 100.0
Panel - 34 5 10 0 0 100.0
b. Matrix comparison:
Not applicable.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Not applicable.
23

[Table 1 on page 23]
	-	34	2	5	0	0	100.0
Test Strip	+	0	0	0	4	42	100.0
	-	34	2	5	0	0	100.0
Cassette
Panel	+	0	0	0	4	42	100.0
	-	34	2	5	0	0	100.0

[Table 2 on page 23]
THC		Drug-
Free
Urine	< -50% of
the cut-off	-50% of the
cut-off to the
cut-off	Cut-off to
+50% of
the cutoff	> +50% of
the cut-off	%
Agreement
Cup	+	0	0	0	10	37	100.0
	-	34	5	10	0	0	100.0
Dip Panel	+	0	0	0	10	37	100.0
	-	34	5	10	0	0	100.0
Test Strip	+	0	0	0	10	37	100.0
	-	34	5	10	0	0	100.0
Cassette
Panel	+	0	0	0	10	37	100.0
	-	34	5	10	0	0	100.0

--- Page 24 ---
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
24